Taysha Gene Therapies Announces Annual Stockholder Meeting
06/13/2022 - 08:39 AM
The Annual Stockholder Meeting on Friday, June 17, 2022 at 10 am ET
DALLAS, June 13, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that its annual stockholder meeting will be held on Friday, June 17, 2022 at 10 am ET via webcast.
The webcast for this meeting will be available in the “Events & Presentations ” section of the Taysha corporate website. A copy of Taysha’s 2021 annual report is available here and in the “Financial Information” section of the Taysha Corporate Website.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com .
Company Contact: klee@tayshagtx.com
Media Contact: carolyn.hawley@canalecomm.com
Taysha Gene Therapies Inc
TSHA Rankings
#681 Ranked by Stock Gains
TSHA Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About TSHA
taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.
